All wild-type (N = 49) | KRAScodon 12, 13 mutations (N = 21) | KRAScodon 61, codon 146, BRAF, NRASor PIK3CAmutations (any other mutations) (N = 12) | ||
---|---|---|---|---|
Complete response | 1 | 0 | 0 | |
Partial response | 18 | 1 | 0 | |
Stable disease | 19 | 11 | 4 | |
Progressive disease | 11 | 9 | 8 | |
Total | 49 | 21 | 12 | |
Response rate (%) | 38.8 | 4.8 | 0 | P = 0.006* (All wild-type vs. Any other mutations) |
Disease control rate (%) | 77.6 | 57.1 | 33.3 | P = 0.006* (All wild-type vs. Any other mutations) |
Progression-free survival [Median (95% CI) (months)] | 6.1 (3.1, 9.2) | 2.7 (1.2, 4.2) | 1.6 (1.5, 1.7) | P < 0.0001** (All wild-type vs. Any other mutations) |
Overall survival [Median (95% CI) (months)] | 13.8 (9.2, 18.4) | 8.2 (5.7, 10.7) | 6.3 (1.3, 11.3) | P < 0.0001** (All wild-type vs. Any other mutations) |
Relative dose intensity | ||||
Irinotecan [Median (range) (%)] | 72.8 (13.0–100) | 81.0 (38.4–100) | 98.0 (49.3–100) | P = 0.108*** |
Cetuximab [Median (range) (%)] | 86.0 (35.7–100) | 86.3 (11.1–100) | 100 (80.0–100) | P = 0.042*** |
Number of treatment cycles [Median (range)] | 12 (1–86) | 5 (1–23) | 3 (1–12) | P < 0.0001*** |